This 12-month, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of pramlintide, an amylin analog, as an adjunct to lifestyle intervention (LSI) in 411 obese, non-diabetic adults. Participants were assigned to various dosing regimens of pramlintide (120, 240, or 360 µg administered twice or three times daily) or placebo,
